Associated tags: Adenosine, ADPKD, Sumitomo Pharma, Adrenoleukodystrophy, AMPK, Euronext Paris, NASH, Fatty liver disease, ALD, Health, Pharmaceutical, Biotechnology, Euronext, DSM-IV codes, Pharmaceutical industry, Clinical Trials, Research, Patient, Science, Imeglimin, Oncology
Locations: NORTH AMERICA, UNITED STATES, PARIS, FRANCE, EUROPE, JAPAN, RARE, MA, TOKYO, CHINA
Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Diabetes,
Clinical Trials,
Other Health,
USD,
Patient,
Adenosine,
DSM-IV codes,
ADPKD,
Sumitomo Pharma,
Safety,
Pharmacokinetics,
European Patent Convention,
JPY,
Merck Serono,
Kidney,
Male,
Adrenoleukodystrophy,
VLCFA,
EUR,
Plasma,
Serono,
Disease,
NASH,
Fatty liver disease,
Patent,
ALD,
AMN,
POC,
Biomarker,
Merck,
EPO,
Pharmaceutical industry As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
Key Points:
- As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
- Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
- For territories not covered by its agreement with Sumitomo Pharma, Poxel is in ongoing discussions with potential partners for Imeglimin.
- Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.
- The Company, which has made significant progress in securing additional financing, is targeting to close, by the end of April, a transaction relating to the monetization of royalties from TWYMEEG® (Imeglimin) sales in Japan.
- Poxel expects that its financial resources will be sufficient to maintain its operations until the finalization of this monetization transaction.
- The Company will communicate its new financial calendar in April 2024 upon completion of this transaction.
Retrieved on:
Thursday, February 15, 2024
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Clinical Trials,
Other Health,
Merck,
Kidney,
USD,
POC,
Adrenoleukodystrophy,
Merck Serono,
EPO,
JPY,
AMN,
Sumitomo Pharma,
European Patent Convention,
Safety,
Biomarker,
EUR,
ALD,
ADPKD,
Serono,
Adenosine,
Pharmacokinetics,
Patent,
Fatty liver disease,
Patient,
Diabetes,
Disease,
NASH,
Plasma,
Male,
DSM-IV codes,
VLCFA,
Pharmaceutical industry Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
Key Points:
- Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
- We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
- Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
- As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.
Retrieved on:
Wednesday, January 3, 2024
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.
Retrieved on:
Thursday, December 21, 2023
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
IRIS,
Imeglimin,
NASH,
Sumitomo Pharma,
Fatty liver disease,
DSM-IV codes,
Pharmaceutical industry POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.
- With the priority objective of relaunching its R&D activities and executing its strategic plan in rare diseases, the Company has focused in recent months on securing additional financing, in particular non-dilutive solutions.
- In this context, the Company entered into exclusive negotiations with a leading investor to monetize royalties from TWYMEEG® (Imeglimin) sales in Japan.
- Poxel’s goal is to finalize one or more of these financing options and/or partnerships by the end of the first quarter of 2024.
Retrieved on:
Wednesday, November 8, 2023
Biotechnology,
Pharmaceutical,
Health,
Adrenoleukodystrophy,
Patient,
Serono,
ALD,
Plasma,
AMN,
Patent,
Biomarker,
Sumitomo Pharma,
Diabetes,
Merck,
SGLT2,
Jaguar 3.4 Litre,
EPO,
Pharmacokinetics,
Male,
DPP4,
Disease,
Prescription,
Marshal of France,
Pioglitazone,
European Patent Office,
EUR,
United States patent law,
Merck Serono,
VLCFA,
Safety,
European Patent Convention,
JPY,
Estonia,
Kidney,
POC,
Pharmaceutical industry,
Imeglimin Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
Key Points:
- Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
- For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
- On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
- Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024
Retrieved on:
Thursday, October 12, 2023
Health,
Other Health,
Other Science,
Research,
Science,
Pharmaceutical,
Biotechnology,
DSM-IV codes,
Fatty liver disease,
NASH,
Management,
Euronext POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at two upcoming investor conferences.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at two upcoming investor conferences.
- Thomas Kuhn, Chief Executive Officer, and Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs, will present the NASH related programs of Poxel during a dedicated virtual presentation, and will be available to investors for one-on-one virtual meetings.
- Healthtech Innovation Days – Paris, France – in-person and virtual conference
Thomas Kuhn, Chief Executive Officer, and other members of the management of Poxel, will be available to investors for one-on-one in person and virtual meetings.
Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Genetics,
Clinical Trials,
NASH,
Adrenoleukodystrophy,
Scientific communication,
ALD,
AMPK,
DSM-IV codes,
Adenosine,
Metabolism,
Polycystic kidney disease,
Fatty liver disease,
R,
ADPKD,
Pharmacology,
Autosome,
Pharmaceutical industry,
Vaccine,
Euronext POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.
- Sophie Bozec, Executive Vice President, R&D Pharmacology and Scientific Communication at Poxel, will host a virtual presentation on “Direct AMPK Activation: From Preclinical to Clinical.
- Perspectives in Rare Metabolic Diseases”.
- The presentation will review Poxel’s molecule PXL770, which is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, focused on rare diseases treatment, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).
Retrieved on:
Tuesday, September 26, 2023
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Clinical Trials,
Diabetes,
ULF,
Adrenoleukodystrophy,
Prescription,
Plasma,
JPY,
Patent,
Patient,
Serono,
Merck,
R,
Estonia,
POC,
Pioglitazone,
Sumitomo Group,
Disease,
Male,
NASH,
Pharmacokinetics,
Sumitomo Pharma,
EPO,
Fatty liver disease,
Leukodystrophy,
Marshal of France,
Rare,
Kidney,
Conference,
Safety,
Abstract,
DPP4,
ALD,
JDS,
Merck Serono,
European Patent Office,
Biomarker,
DSM-IV codes,
AMN,
IRIS,
Scientific communication,
United States patent law,
SGLT2,
VLCFA,
EUR,
European Patent Convention,
Pharmacology,
TZD,
Pharmaceutical industry,
Medical device,
Imeglimin,
Euronext POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
- For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
- On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
- This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.
Retrieved on:
Thursday, September 7, 2023
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including rare metabolic disorders and non-alcoholic steatohepatitis (NASH) , today announced that it will report its financial results for the Half-Year 2023 on Tuesday, September 26, 2023.
Key Points:
- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including rare metabolic disorders and non-alcoholic steatohepatitis (NASH) , today announced that it will report its financial results for the Half-Year 2023 on Tuesday, September 26, 2023.
- The management team will host a video conference call on September 26, 2023, in French at 1:00 pm CEST, and in English, at 8:30 am EDT (New York time) / 2:30 pm CEST (Paris time) to discuss the financial results and provide a corporate update.
- Registration for the video conference call in English is available on the following link: https://app.livestorm.co/newcap-1/presentation-of-poxels-2023-hall-year-...